WuXi AppTec
Search results
Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
Jul 19, 2022 · WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.
$Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics. 服务与解决方案. 药明生物通过开放式、一体化生物制药能力和技术赋能平台 (CRDMO)，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程。 技术与平台. 横跨从药物发现到生产过程的技术平台. 药明合联. 药明生物子公司，极大简化了生物偶联药物的研发和生产流程. 发现. 从靶点发现到先导临床前候选药物的一站式新药发现服务平台。 哺乳动物细胞. 在哺乳动物细胞培养生物制品的发现、开发和cGMP生产方面，我们拥有无与伦比的能力和专业知识. 检测. 通过EMA、ISO（CNAS）和CMA认证的实验室提供高质量、 专业的第三方生物安全性检测服务. 微生物. 大肠杆菌及酵母表达系统，一体化CMC开发及cGMP生产微生物发酵平台.
Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations...
Aug 3, 2022 · China’s WuXi Biologics has announced a 10-year investment plan aimed at establishing a world-class pharmaceutical contract manufacturing center in Singapore. The Singapore Economic Development Board (EDB) is supporting the project.
Jul 20, 2022 · SINGAPORE - Chinese companies WuXi Biologics and WuXi AppTec will be investing up to $4 billion in total in Singapore to grow their research and development (R&D) and manufacturing...
Mar 19, 2024 · WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion.
Find company research, competitor information, contact details & financial data for WUXI BIOLOGICS BIOPHARMACEUTICALS SINGAPORE PRIVATE LIMITED of Singapore. Get the latest business insights from Dun & Bradstreet.
